We will explain collagen diseases and rheumatic diseases from clinical evidence and immunological viewpoints.
Update: August 31, 2022 "Systemic lupus erythematosus" series "2-1-1. Basics of SLE Overview-Omics-IFN (2022.08.30)", "2-1-2. Basics of SLE TLR-BT-Neu (2022.08.30)" has been updated.
| theme | title | |
| 0. Introduction | 0. Introduction (2021.04.26) | |
|---|---|---|
| 2. Systemic lupus erythematosus | 2-1-1. SLE Fundamentals Overview-Omics-IFN (2022.08.30) | |
| 2-1-2. SLE foundation TLR-BT-Neu (2022.08.30) | ||
| 2-5-1. NPSLE recommendation-treatment-pathophysiology (2021.10.05) | ||
| 2-5-2. NPSLE autoantibodies (2021.10.05) | ||
| 3. Scleroderma | 3-1. Scleroderma (SSc) Overview (2021.05.01) | |
| 3-2. Scleroderma (SSc) Specifics - Lung (2021.05.01) | ||
| 3-3. Scleroderma (SSc) Specifics - Pulmonary Hypertension (2021.05.01) | ||
| 3-4. Scleroderma (SSc) Specifics - Skin - Blood Vessels (2021.05.01) | ||
| 3-5. Scleroderma (SSc) Specifics - Kidney - Intestine - Joint (2021.05.01) | ||
| 5. ANCA-associated vasculitis | 5-1.ANCA-associated vasculitis Basic MPO-PR3 | |
| 5-2.ANCA-associated vasculitis Basic NET and complement | ||
| 5-3. ANCA-associated vasculitis Basic immune tolerance and genome | ||
| 5-4.ANCA-associated vasculitis clinical classification criteria guideline | ||
| 5-5. ANCA-associated vasculitis clinical RCT | ||
| 5-6.ANCA-associated vasculitis Clinical EGPA | ||
| 5-7.ANCA-associated vasculitis clinical epidemiology |
